Figure 3
Immunoreactivity of PV, PF or prostate cancer human sera towards EC Dsg3 peptides. Sera: A) control sera from prostate cancer patients; B) Pemphigus foliaceous sera; C) Pemphigus vulgaris sera. Immunoreactivity of each serum was assayed by dot-blot as described under Methods. Indirect IF titer is reported for each PF and PV serum. Antigens: Dsg3, recombinant EC Dsg 3 protein; peptides with low redundancy to the human proteins: Dsg336–44EEMTMQQAK and Dsg349–60 REWVKFAKPCRE; peptide with high affinity to DRB*0402: Dsg3190–204LNSKIAFKIVSQEPA; control peptides: Dsg3373–380QVINVREG and Dsg3518–525NRYTGPYT.